Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P ¼ 0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, Po0.0001). In multivariate analysis, only increasing age (HR 1.04 per year, P ¼ 0.048) and CMV reactivation (HR 5.74, P ¼ 0.001) were significantly associated with paraproteinaemia. Alemtuzumab without CMV reactivation, however, resulted in significantly more paraproteinaemia, suggesting an effect that is independent of CMV reactivation. OS was poorer in patients with paraproteinaemia (HR 2.54, P ¼ 0.04) and relapse increased (HR 2.38, P ¼ 0.087). Paraproteinaemia was not significantly independently associated with decreased survival on multivariate analysis. Post transplant paraproteinaemia is associated with CMV reactivation, is more frequent in alemtuzumab-conditioned transplants and is not associated with improved OS.
Introduction
Paraproteins are monoclonal Igs or Ig light chains that are recognized as the product of a single clone of plasma cells. An excess of these paraproteins in blood is termed as paraproteinaemia or monoclonal gammopathy. Paraproteins form a narrow band or spike in protein electrophoresis.
1 Paraproteinaemia following allo-SCT was first described B40 years ago 2, 3 and has been reported repeatedly since then. [4] [5] [6] [7] [8] [9] [10] Post transplant paraproteinaemia has also been described following auto-SCT [11] [12] [13] and in recipients of solid organ transplants (SOT). [14] [15] [16] [17] [18] There is consensus on several points: (1) paraproteinaemia following allo-SCT is frequent; incidence estimates range from 18 to 100% depending on the patient group studied and sensitivity of detection method. 5, 9, 10 (2) The majority, if not all, of the paraproteins detected are transient. 8, 9 (3) Paraproteins are frequently multiple. 8, 9 (4) Paraprotein Ig heavy-chain isotype reflects the normal frequency distribution, with IgG being the commonest class, followed by IgM and IgA. [7] [8] [9] [10] (5) Finally, there is no evidence of progression to myeloma or lymphoproliferative disorders in patients with paraproteinaemia after allo-SCT. [8] [9] [10] In SOT, there is some evidence that paraproteinaemia is associated with EBVdriven post transplant lymphoproliferative disorder 19, 20 although there is also evidence to the contrary. 14, 21 The variables associated with post transplant paraproteinaemia are still debated. Two reports describe a strong association with the development of GVHD, 8, 9 whereas others have failed to find any association. 7, 10 In SOT there is a strong association between both CMV seropositivity and CMV reactivation and paraprotein development. [14] [15] [16] [17] [18] Paraproteins have also been associated with primary CMV infection and CMV reactivation in both immunocompetent and post transplant immunosuppressed patients. 22 One study has suggested such an association with CMV following allo-SCT 7 although the number of affected patients was small and the association was not statistically significant. Others have failed to find CMV reactivation to be a risk factor. 8 Most reports find that survival is unaffected, although Lim et al. 8 report improved OS in patients with paraproteinaemia in association with chronic GVHD.
In this paper, we report a retrospective analysis of allo-SCT recipients to describe the incidence of post-SCT paraproteinaemia, the role of the T-cell-depleting Ab alemtuzumab, the role of CMV reactivation and the effect on survival of this phenomenon.
Patients and methods

Eligibility
Our institution database was used to identify 104 consecutive allo-SCT procedures performed between 2001 and 2007 with a minimum of 6 months post transplant followup. Patients with myeloma (n ¼ 5) and paraproteinaemia before transplant (n ¼ 2) were excluded. Serum protein electrophoresis data were unavailable for five of the remaining patients. There remained a total of 92 transplants performed in 91 patients-characteristics shown in Table 1 . Written informed consent was obtained from patients and donors before transplantation/stem cell harvest.
Serum protein electrophoresis
Serum protein electrophoresis was scheduled to be performed at 3, 6, 9, 12 and 24 months post transplant. Monoclonal free light chains in the serum were detected by immunoelectrophoresis using semi-automated agarose gel systems (Hydrasys Focusing, Sebia, Camberley, Surrey, UK). Electrophoretic gels were read twice by technicians and any individual serum with a discrete band or a suspected localized band underwent immunofixation (Hydrasys Focusing, Sebia). Paraproteins, particularly IgG and IgM, were most often seen in the gamma region of the electrophoretic strip (occasionally IgA paraproteins were found in the beta region). Following immunofixation, paraprotein concentrations in g/L were quantified using densitometry (Phoresis Software, Sebia). Cumulative incidence of paraproteinaemia was defined as time from transplantation to first detection of paraprotein by serum electrophoresis. Patients without paraproteinaemia were censored at the point of last follow-up. The rate of disappearance of paraproteinaemia was defined as the time from first detection of paraprotein to the first point where it is no longer detected by serum electrophoresis. Patients with persisting paraprotein were censored at point of last serum electrophoresis. Plasma cell dyscrasias and lymphoproliferative disorders were excluded by examination of BM aspirate (and, if indicated, trephine) biopsies.
Conditioning protocols and GVHD prophylaxis
Reduced intensity conditioning was performed using fludarabine (total dose 125 mg/m 2 ) and melphalan (total dose 140 mg/m 2 ). Recipients of unrelated donor transplants also received alemtuzumab (total dose 60 or 90 mg). In three patients conditioning was performed using fludarabine and cyclophosphamide (n ¼ 1), fludarabine and cyclophosphamide with low-dose TBI (n ¼ 1), and with cyclophosphamide and anti-lymphocyte globulin (n ¼ 1). Myeloablative conditioning was performed with cyclophosphamide (120 mg/kg total dose) and TBI in five fractions with or without the addition of alemtuzumab (60 or 90 mg). GVHD prophylaxis comprised ciclosporin A (or tacrolimus if ciclosporin intolerant) given initially 1.5 mg/kg i.v. b.d., subsequently given orally once tolerated. Patients who did not receive alemtuzumab were given GVHD prophylaxis with MTX.
Definitions of GVHD and CMV reactivation
Acute GVHD was defined as GVHD occurring within the first hundred post transplant days. Chronic GVHD was scored as limited or extensive according to the criteria of Shulman et al. 23 Patients were screened for CMV weekly for the first 120 post transplant days by PCR. Reactivation was defined as qualitative CMV transcript detected by PCR at any time point. The PCR reaction was a single round gelbased assay using primers specific for a 149 bp fragment of the CMV glycoprotein B gene as described previously. 24 
Statistical analysis
Differences between patient groups were assessed using Fisher's exact test or the w 2 test for trend for categorical data and the Mann-Whitney U-test for continuous variables. Cumulative incidence and survival curves were estimated using the method of Kaplan and Meier. 25 OS was defined as time from transplant to death from any cause. Relapse incidence was defined as time from transplant to date of relapse with patients being censored at last followup or death. The log-rank test was used to compare incidence and survival curves between different groups. These analyses were performed using GraphPad Prism version 5.03 for Windows (Graphpad Software, San Diego, CA, USA). Multivariate analysis of paraproteinaemia incidence was performed by logistic regression, treating paraproteinaemia as a categorical outcome. Multivariate analysis of survival was performed by Cox proportional hazards, co-variates are listed in the text. Multivariate analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA). A P-value of o0.05 was taken as the level of significance.
Results
Paraprotein incidence and characteristics
A total of fifty-five paraproteins developed in 29 of the 92 transplants (32%). With a median follow-up for surviving patients of 4.75 years, the cumulative incidence was 32% (95% CI: 18-44%), plateauing at 22 months (Figure 1a) . The median time to paraprotein detection was 5 months. Paraproteins were frequently multiple, being monoclonal in 14 cases, bi-clonal in 7 cases and tri-clonal in a further 7 type could be determined in 48 paraproteins-classes were IgG 40 (83%), IgA 5 (10.5%) and IgM 3 (6.5%). In all, 50% of paraproteins were kappa restricted and 50% were lambda restricted. One patient developed six detectable paraproteins. The median number of paraproteins per transplant was two. Most paraproteins were too small to be quantified. The mean concentration of 13 quantifiable paraproteins was 2.85 g/L (range 0.8-10.8 g/L).
In 10 of 29 patients the paraprotein subsequently resolved. The cumulative persistence of paraproteinaemia is illustrated in Figure 1b . With a median time to last serum electrophoresis of 21 months in surviving patients, persistent paraproteinaemia reached a plateau of 47% (95% CI: 23-68%) at 18 months. None of the patients subsequently developed myeloma or a lymphoproliferative disorder, although one patient developed a paraproteinassociated cryoglobulinaemia.
Factors associated with paraprotein development
The characteristics of the 29 transplant patients with paraproteinaemia are compared with those with nondetectable paraprotein in Table 1 . Patients developing paraprotein(s) were found to be older (median age 47 vs 43 years, P ¼ 0.01), more likely to be CMV seropositive (76 vs 46%, odds ratio ¼ 3.69 (95% CI 1.38-9.86), P ¼ 0.01), more likely to have an unrelated donor (66 vs 27%, odds ratio ¼ 5.14 (2-13.3), P ¼ 0.0006) and more likely to have received alemtuzumab (69 vs 30%, odds ratio ¼ 5.15 (1.98-13.4), P ¼ 0.0006). Neither acute nor chronic GVHD was associated with increased paraprotein incidence. The cumulative incidence of paraproteinaemia in patients receiving alemtuzumab vs those who did not is shown in Figure 2a . Paraproteins developed earlier in alemtuzumab recipients and 2-year incidence was 50% (95% CI: 40-63%) vs 18% (95% CI 4-33%) in patients who did not receive alemtuzumab (HR 3.93 (1.81-8.56), P ¼ 0.0006).
The alemtuzumab-conditioned group was examined separately. Paraproteinaemia incidence in alemtuzumab recipients was higher in those patients with chronic GVHD, but not significantly so (HR 1.83 (0.71-4.7), P ¼ 0.26) (Figure 2b ). Paraproteinaemia after allo-SCT P Medd et al CMV reactivation and paraproteinaemia CMV reactivation occurred in 26 of 91 transplant patients (29%, data unavailable for one patient). Median time for CMV reactivation was 33 days (range 4-178). CMV reactivation was more frequent in alemtuzumab recipients: 21 of 38 transplants (55%, data unavailable for 1 patient) vs 5 of 53 transplants (9.4%, data unavailable for 1 patient, Po0.0001). Of 26 patients reactivating CMV, 16 developed a paraprotein. The median time between CMV viraemia first being detected and paraprotein detection was 140 days (range À2 to 553 days). Two-year cumulative incidence of paraproteinaemia was 61% vs 19% for patients with and without CMV reactivation (HR ¼ 7.5 (2.98-18.9), Po0.0001) (Figure 3) . Multivariate analysis by logistic regression was performed using the following co-variates: age at transplant, CMV serostatus, donor type (sibling vs MUD), alemtuzumab use and CMV reactivation. In multivariate analysis, only patient age and CMV reactivation remained significantly associated with increased risk of paraproteinaemia (Table 2) .
We attempted to determine whether the increased paraproteinaemia incidence in alemtuzumab recipients was solely attributable to higher CMV reactivation. The cohort was divided into four patient groups: received alemtuzumab and reactivated CMV (n ¼ 21), received alemtuzumab and did not reactivate CMV (n ¼ 17), did not receive alemtuzumab and reactivated CMV (n ¼ 5), and did not receive alemtuzumab and did not reactivate CMV (n ¼ 48). Cumulative incidence in these groups is shown in Figure 3b . The highest incidence of paraproteinaemia is seen in patients reactivating CMV irrespective of whether they received alemtuzumab or not (2-year incidence 63 and 60%, respectively, HR ¼ 0.84 (95% CI: 0.24-2.9) P ¼ 0.79). In those who received alemtuzumab but did not reactivate CMV, incidence was lower than those receiving alemtuzumab and reactivating CMV (37% at 2 years) but not significantly so (HR ¼ 0.45 (95% CI: 0.18-1.13) P ¼ 0.09). The lowest incidence was in those who received no alemtuzumab and did not reactivate CMV (2-year incidence 13%), significantly lower than the alemtuzumab no CMV reactivation group (HR ¼ 0.22 (95% CI: 0.06-0.85) P ¼ 0.03). These data suggest that alemtuzumab has additional effects (independent of CMV reactivation) that Paraproteinaemia after allo-SCT P Medd et al contribute to the development of post transplant paraproteinaemia.
OS and relapse incidence
The cumulative survival of the paraprotein group was significantly poorer than the paraprotein-free group (2-year survival 75% vs 84%, HR ¼ 2.61 (95% CI: 1.09-6.26), P ¼ 0.03) (Figure 4 ). Cumulative survival in the paraproteinfree group reached a plateau of 76% at 50 months while continuing to diminish in the paraprotein group with several deaths beyond 3 years post transplant (although note that patients with less than 6 months follow-up are excluded from this study). We examined the causes of death in the patients with paraproteinaemia. There were 12 deaths in this group: 8 were due to relapse of the original disease, 2 due to other (non-haematological) malignancies, 1 due to post transplant lymphoproliferative disorder and 1 due to GVHD. Relapsed disease is therefore the commonest cause of death in the group of patients with post transplant paraproteinaemia. There were no deaths attributable to CMV disease in patients with paraproteinaemia. To assess whether the duration of paraproteinaemia was associated with an ultimately poor outcome, we examined the seven patients with paraproteinaemia still detectable at 18 months after allo-SCT. Of these seven, only one has subsequently died. We performed univariate and multivariate analysis in an attempt to determine those transplant variables associated with impaired OS. Univariate analysis was performed for the following co-variates: age (above/below median), sex, diagnosis, disease status at transplant, CMV status, donor type, stem cell source, conditioning intensity, alemtuzumab containing conditioning, CMV reactivation, acute and chronic GVHD, and paraproteinaemia. In univariate analysis, unrelated donor, alemtuzumab use and paraproteinaemia were significantly associated with decreased OS. Multivariate analysis demonstrated only use of an unrelated donor as significantly associated with diminished OS (Table 3 ). The presence of paraproteinaemia remained with an increased hazard ratio for reduced survival (HR ¼ 1.55), but the association was not statistically significant (P ¼ 0.3).
As relapse accounted for the majority of deaths in the paraprotein group, we examined cumulative relapse incidence (RI) for the cohort. Overall relapse incidence at 2 years was estimated to be 19%. Cumulative relapse incidence is shown in Figure 4b ; the estimated 2-year relapse incidences are 32 and 13% for patients with and without paraproteinaemia, respectively (HR 2.38, P ¼ 0.087). Factors that were associated with significantly increased relapse rate by univariate analysis were diagnosis acute leukaemia vs lymphoma (HR 3.24, P ¼ 0.01) and unrelated vs sibling donor (HR 2.7, P ¼ 0.04).
Discussion
Frequent mono-and oligo-clonal paraproteins following allo-SCT are well described. Here we show a paraproteinaemia incidence of 32% following allo-SCT, a figure comparable to others reported (for example, 36% by Lim et al. 8 and 26% by Hebart et al.
7
). This probably reflects the incidence of this phenomenon as detected by the standard electrophoresis techniques in use in clinical immunology laboratories. There is evidence that with more sensitive methods of detection mono/oligo-clonal paraproteins can be detected in 100% of patients post allo-SCT. 9 Like others, we show a predominance of IgG isotype and with an equal kappa/lambda restriction. 9, 10 We also find multiple paraproteins detected in the majority of cases. Most reports on this subject find post transplant paraproteinaemia to be transient; 8, 9 here we report that approximately 50% of paraproteins have resolved by 3 years from first detection, but the curve appears to reach a plateau at this point. Others have described paraproteinaemia at up to 5 years post transplant, 5 although by this point the incidence was no higher than in the general population. Following SOT, persistent paraproteinaemia seems to be much more Paraproteinaemia after allo-SCT P Medd et al frequent. 20, 21 If post transplant paraproteinaemia is a function of lymphoid immunosuppression rather than allo-SCT per se, then the fact that immunosuppression is frequently withdrawn after allo-SCT and not after SOT may explain this difference.
We here show an association between the use of alemtuzumab, which results in profound T-cell depletion, 26 and the risk of developing paraproteinaemia. In SOT there is a strong association between CMV infection and/or reactivation and the development of paraproteinaemia, [14] [15] [16] [17] [18] an association suggested, but not proven, by one previous investigation in allo-SCT. 7 The association with alemtuzumab (known to increase CMV reactivation after allo-SCT 27 ) prompted us to investigate the role of CMV reactivation. We show that CMV reactivation is significantly more frequent in alemtuzumab recipients and is strongly associated with post transplant paraprotein development. In multivariate analysis only CMV reactivation and increasing age (itself a risk factor for CMV seropositivity) are significantly associated with paraprotein development.
Our findings differ from those of Lim et al., 8 who found no association between CMV and post-HSCT paraproteinaemia. One possible explanation for this discrepancy is that in their cohort all received alemtuzumab in conditioning. Here, we show that to an extent CMV reactivation and the use of alemtuzumab-containing conditioning are independent risk factors for the development of post transplant paraproteinaemia. Comparing patients who received alemtuzumab but did not reactivate CMV with those who received it and did reactivate CMV, however, we find no significant difference in incidence. By contrast, the incidence in alemtuzumab recipients without CMV reactivation was significantly higher than in patients free of alemtuzumab and CMV reactivation. This leads us to two conclusions: first, considering alemtuzumab recipients alone, we recapitulate the findings of Lim et al. that CMV reactivation is not significantly associated with post transplant paraproteinaemia; second, that alemtuzumab appears to have an effect other than purely increasing the CMV reactivation rate that results in increased risk of post transplant paraproteinaemia.
One possible explanation for a CMV-independent alemtuzumab effect is that other viral infections are causing paraprotein development. One candidate would be EBV; others have not found an association between EBV and paraproteinaemia. 5, 14, 22 However, Drouet et al. found that co-infection with both CMV and EBV was required for an association with paraproteinaemia in renal transplant patients, 16 and EBV lymphoproliferation has been associated with paraproteinaemia in children following allo-SCT. 4 We did not routinely monitor EBV levels and so cannot test whether an association exists in our patient cohort. It is worth noting that EBV-driven post transplant lymphoproliferative disorders do occur following allo-SCT, especially following T-cell depletion. 28 In SOT, attempts have been made to use paraprotein development as a marker for post transplant lymphoproliferative disorder risk with mixed success. 14, 20 It is interesting to note that one patient with post transplant paraproteinaemia in this study eventually succumbed to post transplant lymphoproliferative disorder.
Here we describe a poorer OS in patients with paraproteins, although the significance of this association is not preserved in multivariate analysis. Unlike Lim et al., we do not show improved OS in association with paraproteinaemia. 8 In our study, the main cause of mortality in patients with paraproteinaemia was relapse of the original disease. The development of a paraprotein is associated with CMV reactivation, itself a reflection of the degree of peri-transplant immunosuppression. It is tempting to speculate that the impaired OS in patients with paraproteinaemia is due to a diminished graft-vs-tumour effect in these more immunosuppressed patients, and post transplant paraproteinaemia may be one marker of this more severely impaired post transplant immune response.
Paraproteinaemia seems to be a more frequent finding in alemtuzumab recipients with a poorer OS. We would not, however, advocate the omission of alemtuzumab from conditioning in the MUD setting outside the context of a clinical trial, as there is a concern that this would be associated with a higher incidence of GVHD in the MUD setting. Rather, we would advocate close monitoring of chimerism in these patients with a view to early treatment with donor lymphocyte infusion in an attempt to pre-empt frank disease relapse.
In summary, mono-and oligo-clonal paraproteins are frequent following allo-SCT. The most powerful risk factor for paraproteinaemia is CMV reactivation, which is much more frequent in alemtuzumab recipients. In addition, alemtuzumab without CMV reactivation seems to increase post-HSCT paraprotein incidence. We show impaired OS in patients with post transplant paraproteinaemia. It has been suggested that after allo-SCT immune reconstitution recapitulates normal B-cell ontogeny, but in a clonally dysregulated manner. 5 Both alemtuzumab and CMV reactivation following allo-SCT also seem to reduce detectable T-and B-cell clonal diversity. 29, 30 We suggest that post transplant paraproteinaemia may be a virally driven phenomenon occurring particularly frequently in the presence of the profound lymphoid immunosuppression caused by alemtuzumab-containing conditioning.
